University of California files appeal over CRISPR patents

The University of California at Berkeley and University of Vienna in Austria have appealed a ruling allowing a research center affiliated with MIT and Harvard to keep valuable patents on a revolutionary gene-editing technology known as CRISPR.

The patent rights could be worth billions of dollars as the technology could revolutionize treatment of genetic diseases, crop engineering and other areas.

The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board in Alexandria, Virginia, in February ruled in favor of Broad Institute, a biological and genomic research center affiliated with MIT and Harvard, that they invented the technology first.

In the appeal, Berkeley and the University of Vienna are seeking a review and reversal of the February decision, which they say did not determine which inventors actually invented the use of the technology in certain cells.

(Reporting by Natalie Grover in Bengaluru; Editing by Anil D’Silva)

Read More at Reuters

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Got 10 Minutes? This Kettlebell Workout Only Has 3 Exercises
Screen kids and teens for obesity, U.S. experts say
How Your Sandwich Changed The World
Why You Should Move Your HIIT Workout to the Pool
Lena Dunham’s Trainer Tracy Anderson Says She Wanted to ‘Feel Better’ and Not Make Her Body ‘Look Different’
Ashley Graham Maintains Her Body Year-Round But Sometimes Still Feels Shy in a Bathing Suit
4 Ideas for Using Herbs You Probably Haven’t Thought Of
Bobbi Brown’s Top 10 Superfoods for Beauty and the Fun Way She Eats Them
5 Father’s Day Gift Ideas for Food-Loving Dads Everywhere
The Making Of Emotions, From Pleasurable Fear To Bittersweet Relief
4 Foolproof Tips to Make Healthy Veggie Chips at Home
A Food-Lover’s Mother’s Day Gift Guide
Here’s Why a Man Died After Swimming With a New Tattoo  
A MRSA Infection Cost Me $300,000—and Nearly Killed Me
Novartis heart drug success opens up new care option
Obamacare replacement bill to take center stage in Senate